GI Partners has acquired a majority stake in eClinical Solutions, a leading provider of digital clinical software and services, to enhance its AI-powered data products and biometric services. This move solidifies eClinical’s position as a reliable partner for pharmaceutical companies seeking to accelerate research and develop new therapies amidst growing trial complexity.
Since its inception in 2012, eClinical has developed technology to address the increasing challenges of clinical data. Its elluminate Clinical Data Cloud® platform optimizes data flows, shortens cycle times, and enhances productivity to prepare clinical trials for the future.
eClinical serves 16 of the top 50 biopharmaceutical companies, leveraging its platform to unlock valuable data insights. Raj Indupuri, CEO of eClinical, emphasizes the enduring mission of providing clients with a data and analytics infrastructure that accelerates treatment delivery to patients.
Bob Arnesen, President of eClinical, commends GI Partners’ expertise in scaling biopharmaceutical technology businesses and understanding the market. He believes the partnership will enable eClinical to execute its strategy of delivering value to clients and partners.
Dave Kreter, Managing Director at GI Partners, recognizes the exceptional business and platform established by eClinical, highlighting its role in facilitating informed decision-making and driving biopharma innovation. GI Partners’ investment supports eClinical’s journey towards expanding its product roadmap and enhancing its embedded AI capabilities, ultimately contributing to future-ready clinical trials.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
